This article is more than 5 years old. Information may no longer be current.

VIDEO: Obeticholic acid improves fibrosis in patients with NASH

ByZobair M. Younossi, MD, MPH

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SAN DIEGO – In this video from Digestive Disease Week, Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, discusses interim results from the phase 3 randomized REGENERATE clinical trial of obeticholic acid for patients with nonalcoholic steatohepatitis.

The researchers’ overall assessment of the trial determined that obeticholic acid (Ocaliva, Intercept) successfully improved fibrosis without worsening steatohepatitis, according to Younossi. In addition, the adverse events were mild to moderate and equal across treatment arms.